Kazia Therapeutics Licenses Paxalisib To Sovargen For Intractable Seizures In Rare Central Nervous System Diseases
Kazia Therapeutics Licenses Paxalisib To Sovargen For Intractable Seizures In Rare Central Nervous System Diseases
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.